Cargando…

Immunogenicity and Safety of a Candidate Subunit Adjuvanted Herpes Zoster Vaccine in Adults with Solid Tumors Vaccinated Before or During Immunosuppressive Chemotherapy Treatment: A Phase II/III, Randomized Clinical Trial

BACKGROUND: No herpes zoster (HZ) vaccine for immunosuppressed individuals is currently available. GSK’s candidate HZ vaccine containing recombinant varicella zoster virus glycoprotein E (gE) subunit and AS01(B) Adjuvant System (HZ/su) showed >90% efficacy for HZ prevention in immunocompetent adu...

Descripción completa

Detalles Bibliográficos
Autor principal:	Vink, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630987/ http://dx.doi.org/10.1093/ofid/ofx163.1045

Ejemplares similares

Immunogenicity and Safety of a Candidate Subunit Adjuvanted Herpes Zoster Vaccine (HZ/su) in Adults Post Renal Transplant: a Phase III Randomized Clinical Trial
por: Vink, Peter
Publicado: (2017)

Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine
por: Grupping, Katrijn, et al.
Publicado: (2017)

Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in Adults with Hematologic Malignancies: A Phase III, Randomized Clinical Trial
por: Oostvogels, Lidia
Publicado: (2017)

Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine: A Phase III, Group-Matched, Clinical Trial
por: Grupping, Katrijn, et al.
Publicado: (2017)

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial
por: Vink, Peter, et al.
Publicado: (2019)

Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial
por: Godeaux, Olivier, et al.
Publicado: (2017)

Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older
por: Schwarz, Tino F, et al.
Publicado: (2017)

4. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Adults
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study
por: Berkowitz, Elchonon M., et al.
Publicado: (2015)

Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularly
por: Vink, Peter, et al.
Publicado: (2016)

Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster
por: Ulaszewska, Marta, et al.
Publicado: (2023)

Comparative preclinical evaluation of AS01 versus other Adjuvant Systems in a candidate herpes zoster glycoprotein E subunit vaccine
por: Fochesato, Michel, et al.
Publicado: (2016)

Optimal gender-specific age for cost-effective vaccination with adjuvanted herpes zoster subunit vaccine in Chinese adults
por: You, Joyce H. S., et al.
Publicado: (2019)

Healthy ageing: Herpes zoster infection and the role of the adjuvanted recombinant zoster vaccine
por: Curran, D, et al.
Publicado: (2022)

A Cost-Effectiveness Analysis of an Adjuvanted Subunit Vaccine for the Prevention of Herpes Zoster and Post-Herpetic Neuralgia
por: Carpenter, Christopher, et al.
Publicado: (2017)

A Cost-effectiveness Analysis of an Adjuvanted Subunit Vaccine for the Prevention of Herpes Zoster and Post-herpetic Neuralgia
por: Carpenter, Christopher F, et al.
Publicado: (2019)

Humoral and Cellular Immunogenicity of Zoster Vaccine within One Year after Herpes Zoster
por: Lee, Eunyoung, et al.
Publicado: (2017)

2483. Twelve-Month Immunogenicity and Safety of an Adjuvanted Recombinant Zoster Vaccine in Immunosuppressed Adults Post Renal Transplant: a Phase III Randomized Clinical Trial
por: Vink, Peter, et al.
Publicado: (2018)

Herpes Zoster Vaccination
por: Kim, Kyung Hoon
Publicado: (2013)

Herpes Zoster Vaccines
por: Harbecke, Ruth, et al.
Publicado: (2021)

Herpes Zoster and Immunogenicity and Safety of Zoster Vaccines in Transplant Patients: A Narrative Review of the Literature
por: Wang, Lei, et al.
Publicado: (2018)

Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination
por: Strezova, Ana, et al.
Publicado: (2022)

The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

A novel nonlive, adjuvanted herpes zoster subunit vaccine: a report on the emerging clinical data and safety profile
por: Brosio, Federica, et al.
Publicado: (2018)

Herpes zoster vaccine in Korea
por: Choi, Won Suk
Publicado: (2013)

Vaccine against herpes zoster
por: Pasternak, Jacyr
Publicado: (2013)

Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines
por: de Boer, Pieter T., et al.
Publicado: (2018)

Safety and immunogenicity of an AS01-adjuvanted varicella zoster virus subunit candidate vaccine (HZ/su): A phase-I, open-label study in Japanese adults
por: Lal, Himal, et al.
Publicado: (2013)

Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination
por: Bruxvoort, Katia J, et al.
Publicado: (2022)

Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial
por: Vink, Peter, et al.
Publicado: (2020)

Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines
por: Marra, Yasmin, et al.
Publicado: (2022)

Status of Herpes Zoster and Herpes Zoster Vaccines in 2023: A position paper
por: García, José María Molero, et al.
Publicado: (2023)

Effects of Adjuvants on the Immunogenicity and Efficacy of a Zika Virus Envelope Domain III Subunit Vaccine
por: Wang, Xinyi, et al.
Publicado: (2019)

Cost-Effectiveness of Herpes Zoster Vaccination
por: Sriwijitalai, Won, et al.
Publicado: (2019)

Herpes zoster after COVID vaccination
por: van Dam, C.S., et al.
Publicado: (2021)

Herpes zoster following COVID-19 vaccination in an immunocompetent and vaccinated for herpes zoster adult: A two-vaccine related event?
por: Vallianou, Natalia G., et al.
Publicado: (2022)

Persistence of Immune Response to an Adjuvanted Varicella‐Zoster Virus Subunit Candidate Vaccine for up to Year 9 in Older Adults
por: Pauksens, Karlis, et al.
Publicado: (2017)

Healthy ageing: Herpes zoster infection and the role of zoster vaccination
por: Curran, Desmond, et al.
Publicado: (2023)

Immunogenicity and safety of a live herpes zoster vaccine in hematopoietic stem cell transplant recipients
por: Chun, June Young, et al.
Publicado: (2021)

Comment on “Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine”
por: Giannelos, Nikolaos, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4tlcp7q8l90a5g7t004o9mvqk1